Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or
deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease …

Of the various types of hemophilia, the most common of these lifelong bleeding disorders
are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these …

Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence‐
based guidelines offer practical recommendations on the diagnosis and general …

Gender inequality damages the health of millions of girls and women across the globe. It can
also be damaging to men's health despite the many tangible benefits it gives men through …

Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation
factor IX (F. IX). Previously, we established an experimental basis for gene transfer as a …

Current factor VIII (FVIII) products display a half-life (t1/2) of∼ 8-12 hours, requiring frequent
intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is …

The previously published mortality studies are limited in hemophilia populations but suggest
that there is no increased risk of mortality in factor VIII inhibitor patients. This retrospective …

As the management of haemophilia is complex, it is essential that those with the disorder
should have ready access to a range of services provided by a multidisciplinary team of …

Current factor IX (FIX) products display a half-life (t1/2) of∼ 18 hours, requiring frequent
intravenous infusions for prophylaxis and treatment in patients with hemophilia B. This open …

Against a background of a rapidly evolving treatment landscape, a contemporary, evidence‐
based consolidated understanding of mortality in people with congenital hemophilia A …